Eisai Announces roduction & Shipment Commencement of Aricept, an Alzheimer's Disease Treatment, From US Manufacturing Facility
Tokyo (November 24, 1998) - Eisai Co., Ltd. of Tokyo (President and CEO: Haruo Naito) today announced production and shipment commencement of ARICEPT, a treatment for mild to moderate Alzheimer's disease, from the Company's US subsidiary, Eisai Inc., manufacturing facility in North Carolina which conducts formulation research and commercial production.
The U.S. Food and Drug Administration (FDA) granted manufacturing approval for ARICEPT on November 5, and production began in early November with product shipments commencing on November 23. In the future, production of the proton pump inhibitor, ACIPHEX which is presently under review by the FDA, may also occur at the facility.
With the commencement of commercial production, Eisai has established a full range of pharmaceutical functions in the United States ranging from basic research, clinical research, manufacturing, to marketing and sales.
Eisai Co., Ltd. is a research-based human health care company which discovers, develops and markets products in more than 30 countries. Through its global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of worldwide health care systems. The company reported sales of about $2.3 billion in 1997 with approximately 15 percent of sales spent for research and development.